We have reported that von Hippel-Lindau protein (pVHL) expression is elevated in human and mouse fibrotic lungs and that overexpression of pVHL stimulates fibroblast proliferation. We sought to determine whether loss of pVHL in fibroblasts prevents injury and fibrosis in mice that are treated with bleomycin. We generated heterozygous fibroblast-specific pVHL knockdown mice (Fsp-VHL Suppression of pVHL also decreased bleomycin-induced Wnt signaling and PGE 2 signaling but did not affect bleomycin-induced initial acute lung injury and lung inflammation. These results indicate that pVHL has a pivotal role in bleomycin-induced pulmonary fibrosis, possibly via a HIF-independent pathway. Paradoxically, pVHL does not affect bleomycin-induced lung injury and inflammation, indicating a separation of the mechanisms involved in injury/inflammation from those involved in pulmonary fibrosis.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a devastating disease associated with progressive and irreversible destruction of the lung architecture (1, 2) . The cause of IPF remains largely unknown and the annual incidence of IPF is between 4.6 and 16.3 per 100000 people and is rising (1) (2) (3) (4) . IPF patients have a poor median survival of 2.5-3.5 years after diagnosis and the treatment options are limited to lung transplantation (1, 3, 4) . Hallmarks of pulmonary fibrosis include lung fibroblast proliferation, activation, differentiation, and exaggerated deposition of extracellular matrix (ECM) proteins, especially collagen and fibronectin (5, 6) . However, the detailed molecular mechanisms underlying altered fibroblast biology during fibrosis remain elusive.
Von Hippel-Lindau protein (pVHL) was first identified as a tumor suppressor because the mutation of VHL gene was associated with tumors via activation of hypoxia-inducible factor (HIF) (7) (8) (9) (10) (11) ; however, mounting evidence suggests that pVHL also has HIF-independent functions in cytoskeleton dynamics, alveolar epithelial functions (12, 13) , epithelial cilia maintenance (14) , extracellular matrix assembly, and cell proliferation (14) (15) (16) (17) (18) (19) (20) (21) . Although the function of pVHL in human disease is mostly elucidated in a lossof-function fashion (22) , recent reports have shown that expression levels of the VHL gene and protein are increased in patients with chronic obstructive pulmonary disease (COPD) and IPF (23, 24) .
We have previously reported that lungs from patients with IPF express increased levels of pVHL in fibroblastic foci (24) . Bleomycin treatment also induces pVHL in mouse lung fibroblasts but not in alveolar type II cells (24) . Overexpression of pVHL increases lung fibroblast proliferation, induces fibronectin, collagen, and fibronectin receptor α5 integrin subunit, and increases activation of focal adhesion kinase (FAK) (24) . Moreover, suppression of pVHL prevents TGF-β1-induced proliferation of mouse embryonic fibroblasts (24) . These results indicate that elevated expression of pVHL results in the aberrant expression of fibronectin and collagen, activation of integrin/FAK signaling, fibroblast proliferation, and fibrosis and suggest that pVHL may have a role in the molecular pathogenesis of IPF.
In this study, we provide novel evidence that fibroblast-specific pVHL is required for the development of pulmonary fibrosis in mice treated with bleomycin. We generated novel strains of fibroblast-specific knockout or knockdown mice in order to determine whether suppression of pVHL in fibroblasts prevents bleomycin-induced fibrosis independent of HIF activation. Paradoxically, we found that pVHL does not appear to affect bleomycin-induced lung injury and inflammation, indicating a specific role of pVHL on pulmonary fibrosis only. Moreover, suppression of pVHL inhibits activation of Wnt and rescues the antifibrotic PGE signaling. Together, our results indicate that pVHL plays a role in the development of pulmonary fibrosis.
MATERIALS AND METHODS

Mice
Homozygous vhlh 2-lox mice (provided by Dr. Volker Haase of Vanderbilt University) and homozygous Fsp-Cre mice (provided by Drs. Anthony J. Trimboli from laboratories of Dr. Gustavo Leone and Michael C. Ostrowski of Ohio State University) were crossbred and backcrossed to generate mice with fibroblast-specific knockout of pVHL (25, 26) . Tail DNA from offspring was examined by PCR to confirm the genotypes with the primers listed in Table S1 on a Mastercycler epGradient S model (Eppendorf, Hamburg, Germany) (25, 26) . Animal studies were conducted according to National Institutes of Health guidelines and the experimental protocols were approved by the University of Illinois at Chicago Institutional Animal Care and Use Committee.
Delivery of bleomycin and PBS to mouse lungs
Fifty microliters of saline or bleomycin (0.045 units, Sigma-Aldrich, St. Louis, MO) dissolved in saline was delivered intratracheally as described previously (24, 27) . Briefly, animals were sedated and secured.
A flexible metal wire guided the placement of an angiocath and bleomycin was administered by direct instillation into the angiocath (two 25-μL aliquots 2 minutes apart) using a Hamilton syringe.
Measurements of PGE 2 by mass spectrometry
Quantitative analysis of PGD 2 and PGE 2 were carried out by UHPLC and mass spectrometry as described previously (28) . Briefly, the samples were separated using UHPLC on a Shimadzu (Columbia, MD) Nexera UHPLC system equipped with an Acquity (Waters, Milford, MA) UPLC BEH C 18 (2.1 mm × 50 mm, 1.7 μm) analytical column at 50°C. An isocratic mobile phase was used consisting of acetonitrile/aqueous 0.1% formic acid (40:60, v/v) at a flow rate of 1.2 ml/min. The UHPLC system was interfaced to a Shimadzu (Kyoto, Japan) LCMS-8040 triple quadruple mass spectrometer that was operated using negative ion electrospray. Isomeric PGD 2 and PGE 2 were measured using a selected reaction monitoring transition of m/z 351 to m/z 271, and the transition of m/z 355 to m/z 275 was selected for the internal standards d4-PGE 2 and d4-PGD 2 .
Flow cytometry analysis
Mouse lung fibroblasts (MLF) were isolated from pVHL wild type or knockout mice and plated. For each sorting, we collected 4x10 6 
Statistical analysis
Results were expressed as mean ± SEM. Data were analyzed using one-way analysis of variance (ANOVA). When the ANOVA indicated a significant difference, we performed the Bonferroni correction post-test to compare all individual groups. Statistical significance was set at a 0.05 level.
Detailed Methods can be found in the online supplement.
RESULTS
Fibroblast-specific knockout of pVHL and activation of HIF
We had already reported that pVHL is upregulated in fibroblasts in fibrotic tissues and that overexpression of pVHL induces fibroblast proliferation (24) , suggesting that pVHL may play a role in the development of IPF. To address this, we investigated whether loss of pVHL prevents fibrosis. We generated strains of fibroblast-specific pVHL knockdown (Fsp-VHL (Fig 1A) (25, 26) . vhlh 2-lox mice contain two loxP sites flanking the VHL promoter and the first exon, and they develop normally. In Fsp-Cre mouse, Cre expression is driven by the fibroblastspecific protein 1 (Fsp-1; also known as S100A4) promoter (26, 29 ligase that targets HIFα for proteosome degradation and loss of pVHL increases HIF activity (22, 32) . As expected, Fsp-VHL -/-mice displayed elevated levels of hematocrit (HCT), red blood cells (RBC), and hemoglobin (HGB) (Fig 1D-1F) . However, Fsp-VHL +/-mice displayed the same levels of RBC, HCT, and HGB as wild type mice (Fig 1D-1F) . 
Suppression of fibroblast-specific pVHL prevents bleomycin-induced fibrosis in vivo
To assess whether pVHL is required for bleomycin-induced fibrosis, we administered 0.045 U bleomycin/mouse intratracheally to VHL +/+ , Fsp-VHL
, and Fsp-VHL -/-mice. Mice administered with the same volume of PBS were used as control. Twenty-one days after administration, we collected the lung tissues of these mice and determined the collagen contents, a hallmark of fibrosis. As shown in Fig   2A , despite a slight increase of basal collagen levels in Fsp-VHL -/-mice, bleomycin-induced collagen expression was inhibited in both Fsp-VHL +/-and Fsp-VHL -/-mice. Similarly, elevation of the mRNA levels of col1a1 and col1a2 was inhibited in Fsp-VHL +/-and Fsp-VHL -/-mice (Fig 2B and 2C) . We confirmed these observation with Masson's Trichrome staining (Fig 2D) . These results suggest a HIFindependent function of pVHL in the pathogenesis of pulmonary fibrosis.
Suppression of fibroblast-specific pVHL prevents bleomycin-induced fibroblast proliferation, differentiation, and matrix protein dysregulation in vivo and in vitro
Pulmonary fibrosis is associated with fibroblast proliferation, differentiation, and ECM protein dysregulation. To determine whether suppression of pVHL may prevent fibrosis via inhibition of fibroblast proliferation in vivo, we determined the expression levels of PCNA in the lung tissues collected
, and Fsp-VHL -/-mice 21 days after administration of PBS or bleomycin. We found that bleomycin-induced PCNA was inhibited in Fsp-VHL +/-and Fsp-VHL -/-mouse lungs (Fig 3A) .
We also found that suppression of pVHL inhibited bleomycin-induced α-SMA (Acta2) (Fig 3B) . These data suggest that suppression of fibroblast-specific pVHL inhibits fibroblast proliferation and cells (~90%) (Fig 3C) . We collected these PCNA + MLF and compared the expression levels of proteins that participate in fibrosis. We found that PCNA + MLF from Fsp-VHL -/-mice expressed lower levels of integrin α5 and MMP9 than those from VHL fl/fl and Fsp-VHL +/-mice. However, levels of α-SMA, collagen, fibronectin (Fn), and PCNA remained the same in these mice (Fig 3D) . These results suggest that pVHL is required for the maintenance of integrin α5 and MMP9 in proliferating fibroblasts.
During fibrosis, expression of ECM proteins is dysregulated. Previously, we have shown that overexpression of pVHL stimulates expression of fibronectin and integrin α5β1 and activates FAK in lung fibroblasts, leading to fibroblast proliferation (24) . We showed that in mouse lungs collected 21 days after administration of PBS and bleomycin, suppression of pVHL in fibroblasts prevented the expression of integrin α5 (Fig 3E) . MMP2 and MMP9 regulate the dysregulation of ECM during fibrosis (33, 34) .
Although suppression of pVHL had little effect on bleomycin-induced MMP2, MMP9 expression was inhibited in these mice (Fig 3F-3G) . These results indicate that pVHL may regulate fibroblast ECM deposition via a MMP9-specific pathway. Consistently, suppression of MMP9 in N12 normal human lung fibroblasts did not alter expression levels of MMP2, Fn, collagen, PCNA, or integrin α4 and α5, but it was able to inhibit integrin β1 (Fig 3H-3I) . Thus, pVHL may regulate fibroblast ECM via an integrin α5 and MMP9/integrin β1 pathway.
To determine the effect of pVHL on the early fibrotic responses, we determined the expression levels of these genes in the lung tissues from VHL +/+ , Fsp-VHL
, and Fsp-VHL -/-mice 5 days after administration of PBS or bleomycin. We found that bleomycin-induced PCNA, MMP2, and MMP9 were inhibited in Fsp-VHL +/-and Fsp-VHL -/-mouse lungs, whereas α-SMA (Acta2) levels were similar in these mice (Supplemental Fig S1) . Interestingly, we found that collagen (col1a1 and col1a2) and integrin α5 were upregulated in bleomycin-treated Fsp-VHL +/-and Fsp-VHL -/-mice (Supplemental Fig S1) . Therefore, in spite of the differential regulation of fibrotic responses in the early and late stage, the requirement of pVHL for bleomycin-induced MMP9 is preserved in both stages.
The Wnt/Frizzled pathway is essential for the pVHL-mediated ECM dysregulation during fibrosis
Emerging data suggest that Wnt signaling plays a critical role in IPF (35) (36) (37) (38) . IPF patients have elevated levels of Wnt-2b, 5b, and Fz-related proteins, and β-catenin targets are known to promote fibrosis or proliferation (39) (40) (41) . Although the Wnt ligands are distinct, they share the same core elements in canonical Wnt signaling through β-catenin stabilization and translocation to the nucleus. To study whether pVHL regulates Wnt signaling, we overexpressed pVHL in N12 normal human lung fibroblasts and performed a microarray analysis, observing that overexpression of pVHL increased Wnt signaling (Fig 4A) . In Fsp-VHL +/-and Fsp-VHL -/-mouse lungs harvested 21 days after administration of PBS or bleomycin, bleomycin-induced expression of Wnt5b and Wnt16 was inhibited (Fig 4B and 4C) .
Although bleomycin had little effect on Lrp6 expression, suppression of pVHL decreased Lrp6 expression in bleomycin-treated mice (Fig 4D) . These results suggest a correlation between Wnt signaling and pVHL expression. Similarly, in mouse lungs harvested 5 days after administration of PBS or bleomycin, we found that deletion of pVHL had limited effects on Wnt2 between PBS-and bleomycin-treated mice;
however, deletion of pVHL inhibited bleomycin-induced Wnt2b, Wnt5b, and Wnt16 (Supplemental Fig   S2) . These results show that the pVHL is required for the bleomycin-induced Wnt5b and Wnt16 in both the early and late stages of fibrosis.
To assess the significance of this pVHL-Wnt link, we overexpressed Wnt5b and Wnt16 in N12 normal human lung fibroblasts by adenoviruses infection. We found that overexpression of Wnt5b and Wnt16 increased expression of Fn, integrin α5, intergin β1, and collagen, while decreasing expression levels of integrin α4, MMP2, and MMP9 at various degrees (Fig 4E) . However, overexpression of Wnt5b and Wnt16 had little effect on expression levels of PCNA (Fig 4E) . Interestingly, overexpression of Wnt16 also induced levels of Wnt5b (Fig 4E) . These results suggest that pVHL-mediated expression of integrinα5β1/Fn is controlled by the Wnt5b/Wnt16 signaling pathway.
Suppression of pVHL protects against bleomycin-mediated suppression of PGE 2 and PGD 2 in the fibrotic stage
Recent studies have indicated that IPF is characterized by a loss in production of prostaglandins, including prostaglandin (PG) E 2 (42) (43) (44) . PGE 2 signaling can suppress fibrogenesis by limiting lung myofibroblast differentiation and migration (44, 45) . We showed that bleomycin-induced fibrotic lungs have decreased PGE 2 levels, whereas Fsp-VHL +/-and Fsp-VHL -/-mice retained PGE 2 and PGD 2 levels after belomycin administration (Fig 5A-5B) , suggesting that knockdown or knockout of pVHL prevents pulmonary fibrosis via maintaining the homeostasis of PGE 2 signaling.
PGE 2 is synthesized from PGH 2 , and this conversion is catalyzed by prostaglandin synthase enzymes (e.g., PGE synthases) (44, 46 bleomycin induced the expression of COX-1, COX-2, PGE synthase 1 and 3, and EP2 (Fig 5C-5H) , which is consistent with previous reports that there is compensatory induction of PGE 2 production and COX-2 expression shortly after bleomycin treatment (49, 50) . However, PGE synthase2 levels remained unchanged (Fig 5F) . Interestingly, Fsp-VHL +/-and Fsp-VHL -/-mice did not appear to have this compensation in the belomycin-treated group (Fig 5C-5F ). These results indicate that suppression of pVHL is sufficient to maintain PGE 2 homeostasis and prevent fibrosis.
Suppression of pVHL in fibroblasts has no effect on bleomycin-induced lung injury and inflammation in vivo
Inflammation may precede fibrosis and inflammatory cells may secret profibrotic cytokines to activate fibroblasts, contributing to fibrosis (51, 52) . In bleomycin-induced lung fibrosis, there is an initial acute lung injury and inflammatory response (27, 53) (Fig 6A-6C ). TGF-β1 is a potent pro-fibrotic cytokine; however, suppression of pVHL did not alter bleomycininduced production of TGF-β1 in BALF (Fig 6D) . We also measured the gene expression levels of cytokines that participate in fibrosis in these mice. We found that deletion of pVHL had little effect on IL1a, IL-1b, and IL-10 after bleomycin treatment, but the deletion inhibited bleomycin-induced IL-6 (Supplemental Fig S2) . These results suggest that pVHL has limited effects on bleomycin-mediated lung injury and inflammation.
DISCUSSION
The current paradigm presumes that loss of pVHL enhances HIF, which drives fibrosis via promoting epithelial mesenchymal transition or pulmonary hypertension (22, 32, 56) . Intriguingly, we have previously shown that pVHL is upregulated in fibrotic fibroblasts, and overexpression of pVHL promotes fibroproliferation and expression of collagen and fibronectin, independently of HIF (24) . Consistently, our data show that Fsp-VHL +/-and Fsp-VHL -/-mice are resistant to bleomycin-induced fibrosis (Fig 2) .
These results suggest that fibroblast-specific pVHL is required for fibrosis using mouse models.
Moreover, our data show that both Fsp-VHL +/-(HIF is not activated, Fig 1) and Fsp-VHL -/-(HIF is activated, Fig 1) mice are resistant to bleomycin-induced fibrosis (Fig 2) ; this suggests a HIF-independent function of pVHL is required in fibrogenesis. This notion is consistent with our previous report that overexpression of pVHL mediates fibroblast proliferation and expression of collagen and fibronectin in a HIF-independent but fibronectin/integrin/FAK-dependent pathway (Fig 7) (24) . Therefore, our research provides new evidence supporting a gain-of-function mechanism for pVHL in fibrosis in addition to the use of a loss-of-function model and indicates that HIF-independent functions of pVHL may also be involved in promoting fibrogenesis.
We would also point out that there is a mild increase of collagen in Fsp-VHL -/-mice, even without treatment of bleomycin, suggesting a spontaneous fibrosis in these mice. Similarly, Hickey and colleagues have reported that mice with a mutation of pVHL at codon 200 (R200W) develop pulmonary vascular remodeling, hemorrhage, edema, and macrophage infiltration, as well as fibrosis in the later stage, presumably via a HIF2-dependent function (32) . It is possible that, in Fsp-VHL -/-mice, loss of both alleles of VHL stabilizes HIF, which promotes the extravasation of fibrocytes to the injurious sites, resulting in fibrosis (4, (57) (58) (59) . Therefore, the role of pVHL in fibrosis may be complex and may vary depending on both HIF-independent and HIF-dependent functions.
Fibrosis is characterized by fibroblast proliferation and differentiation to myofibroblasts as well as dysregulation of extracellular matrix protein. Suppression of fibroblastic pVHL appears to inhibit PCNA and α-SMA expression in bleomycin-treated mice (Fig 3A-3B) , suggesting that fibrotic pVHL is necessary for fibroblast proliferation and differentiation. We have reported that overexpression of pVHL promotes fibroblast proliferation via an integrin α5-dependent mechanism (24) . Consistently, our results
show that suppression of fibroblastic pVHL attenuates the induction of bleomycin-induced integrin α5
( Fig 3E) . ECM protein synthesis and degradation are regulated by MMPs, among which MMP2 and MMP9 are upregulated in IPF (60) . We have also found that both MMP2 and MMP9 mRNA are upregulated in bleomycin-treated mice and that suppression of pVHL only inhibits bleomycin-mediated induction of MMP9 (Fig 3F-3G) , suggesting a MMP9-specific pathway in pVHL-mediated fibrosis, similar to administration of high dose adenovirus-mediated fibrosis (61).
IPF patients have elevated levels of Wnt2, Wnt2b, Wnt5b and Fz-related protein known to promote fibrosis (39) (40) (41) . In addition, inhibition of the Wnt/β-catenin signaling prevents bleomycin-induced lung fibrosis in mice (62) . Our results demonstrate that overexpression of pVHL increases Wnt signaling in fibroblasts while suppression of pVHL inhibits bleomycin-induced Wnt5b and Wnt16 and decreases Lrp6 expression in bleomycin-treated mice (Fig 4) . Thus, these results provide a link between pVHL-Wntfibrosis. However, how pVHL regulates Wnt signaling remains unclear and warrants further investigation.
During fibrosis, reduced production of PGE 2 promotes fibrogenesis via induction of limit lung myofibroblast differentiation and migration (42) (43) (44) (45) . Consistently, we found that bleomycin-induced fibrotic lungs have decreased PGE 2 levels, whereas Fsp-VHL +/-and Fsp-VHL -/-mice retain PGE 2 levels after bleomycin administration (Fig 5F-5B) , suggesting a role for pVHL in regulating the homeostasis of PGE 2 signaling. Previous reports suggest that, in belomycin-treated mice, there is a compensatory induction of PGE signaling genes (49, 50) . We found that Fsp-VHL +/-and Fsp-VHL -/-mice did not appear to have this compensatory induction of COX-1, COX-2, PGE synthase1 and 3, and EP2 (Fig 5C-5H) ,
further confirming the role of pVHL in the homeostasis of PGE2 signaling. Future studies are warranted to elucidate the molecular mechanisms underlying this regulation.
Bleomycin administration is known to induce acute lung injury and lung inflammation, which is accompanied with elevated levels of pro-inflammatory cytokines. However, knockout of pVHL had little effects on BALF protein amount, total cell counts, and differential cell counts (Fig 6A-6C) , suggesting a limited effect of pVHL on lung injury. Moreover, bleomycin-induced TGF-β1 is comparable between wild type mice, Fsp-VHL +/-mice, and Fsp-VHL -/-mice, suggesting a limited role of pVHL in bleomycininduced TGF-β1signaling (Fig 6D) . Although the gene expression patterns at day 5 and day 21 after In summary, our data suggest that pVHL plays a role in pulmonary fibrosis by regulating fibroblast proliferation and differentiation in a HIF-independent pathway and that pVHL regulates the homeostasis of MMP9, Wnt signaling, and PGE 2 signaling (Fig 7) . pVHL may act at multiple levels such as fibronectin/integrinα5β1/FAK, PGE 2 , and Wnt/Frizzled pathways to coordinately regulate fibroblast proliferation, differentiation, and migration during fibrogenesis.
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